Antisense oligonucleotide therapy for spinocerebellar ataxia type 2 …………… Scoles DR, Meera P, Schneider MD, Paul S, Dansithong W, Figueroa KP, Hung G, Rigo F, Bennett CF, Otis TS, Pulst SM. Nature. 2017 Apr 20;544(7650):362-366. PubMed 00
Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice …………… Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, Messing J, Kim HJ, Soriano A, Auburger G, Pulst SM, Taylor JP, Rigo F, Gitler AD. Nature. 2017 Apr 20;544(7650):367-371. PubMed 00
Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides …………… Wang S, Sun H, Tanowitz M, Liang XH, Crooke ST. Nucleic Acids Res. 2017 Apr 3. PubMed 00
Therapeutic Effect of Novel Single-Stranded RNAi Agent Targeting Periostin in Eyes with Retinal Neovascularization …………… Nakama T, Yoshida S, Ishikawa K, Kubo Y, Kobayashi Y, Zhou Y, Nakao S, Hisatomi T, Ikeda Y, Takao K, Yoshikawa K, Matsuda A, Ono J, Ohta S, Izuhara K, Kudo A, Sonoda KH, Ishibashi T. Mol Ther Nucleic Acids.…